Heart Failure Diagnosis and Treatment Guidelines

Diagnostic Approach

The American Heart Association uses a four-stage progressive classification system (A through D) where each stage requires specific diagnostic steps and escalating therapeutic interventions aimed at preventing progression and reducing mortality 1, 2
The AHA/ACC framework divides heart failure into four progressive stages, with each stage representing worsening prognosis and requiring more intensive intervention 1, 2, 3
Initial clinical assessment should determine five critical elements: adequacy of systemic perfusion, volume status, precipitating factors/comorbidities, whether this is new-onset or chronic exacerbation, and the ejection fraction category 5
History and physical examination should focus on specific findings, including symptoms such as dyspnea, fatigue, and exercise intolerance, as well as signs of congestion and hypoperfusion 5, 6, 7
Initial laboratory testing should include a complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, and serum creatinine, among others 6, 7
Natriuretic peptide testing, such as BNP or NT-proBNP, is essential when the diagnosis is uncertain and should be interpreted in context with all clinical data 5, 7
Electrocardiogram and chest radiograph are mandatory in all patients at initial presentation 6, 7
Echocardiography is required during initial evaluation to determine LVEF, chamber size, wall thickness, and valve function 6, 7

For Stage A (at risk, no structural disease, no symptoms), focus exclusively on aggressive risk factor modification to prevent development of structural heart disease, including treating hypertension, managing hyperlipidemia, controlling diabetes, and promoting regular physical activity 1, 2, 4
For Stage B (structural disease, no symptoms), all patients with reduced ejection fraction must receive ACE inhibitors (or ARBs) and beta-blockers to prevent symptomatic heart failure and reduce mortality 1, 2, 9, 4
For Stage C (symptomatic heart failure), patients with fluid retention require immediate diuretic therapy, and quadruple therapy (ACE inhibitor/ARB/ARNI + beta-blocker + mineralocorticoid receptor antagonist + SGLT2 inhibitor) is now the foundation for HFrEF (LVEF ≤40%) 5, 7, 9
For Stage D (advanced/refractory heart failure), consider specialized interventions such as implantable cardioverter-defibrillators, ventricular assist devices, and heart transplantation evaluation 4, 9

Schedule early follow-up within 7-14 days after hospital discharge 4
Regularly monitor renal function, electrolytes, and signs of worsening heart failure, and adjust medications as needed 7, 4, 9
Educate patients on daily weight monitoring, moderate sodium restriction, fluid restriction if needed, medication adherence, and recognition of worsening symptoms 4